Ademi investigates XOMA Royalty fair valuation

News provided by Ademi LLP Apr 27, 2026, 10:00 ET Share this article Share to X Share this article Share to X MILWAUKEE , April 27, 2026 /PRNewswire/ -- Ademi LLP is investigating XOMA (NASDAQ: XOMA ) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Ligand. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

XOMA stockholders will receive $39.00 per share in cash, representing a total equity value of approximately $739 million. The transaction includes an additional contingent value right for XOMA stockholders related to ongoing litigation proceeds. XOMA insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for XOMA by imposing a significant penalty if XOMA accepts a competing bid. We are investigating the conduct of the XOMA board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights.

For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts Ademi LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 SOURCE Ademi LLP 21 % more press release views with Request a Demo × Modal title